

Latin America, Middle East & Africa Cancer Immunotherapy Market (2018 - 2024)

<https://marketpublishers.com/r/LA5F0A8F261EN.html>

Date: December 2018

Pages: 86

Price: US\$ 1,500.00 (Single User License)

ID: LA5F0A8F261EN

Abstracts

The Latin America, Middle East and Africa Cancer Immunotherapy Market would witness market growth of 15.5% CAGR during the forecast period (2018 – 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.

Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 LAMEA Cancer Immunotherapy Market, by Technology
 - 1.4.2 LAMEA Cancer Immunotherapy Market, by Application
 - 1.4.3 LAMEA Cancer Immunotherapy Market, by End User
 - 1.4.4 LAMEA Cancer Immunotherapy Market, by Geography
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY

- 3.1.1 LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
- 3.1.2 LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
- 3.1.3 LAMEA Other Technology Cancer Immunotherapy Market by Country

CHAPTER 4. LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION

- 4.1.1 LAMEA Cancer Immunotherapy Lung Cancer Market by Country
- 4.1.2 LAMEA Cancer Immunotherapy Breast Cancer Market by Country
- 4.1.3 LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
- 4.1.4 LAMEA Cancer Immunotherapy Melanoma Market by Country
- 4.1.5 LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
- 4.1.6 LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
- 4.1.7 LAMEA Other Application Cancer Immunotherapy Market by Country

CHAPTER 5. LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER

- 5.1.1 LAMEA Hospitals Cancer Immunotherapy Market by Country
- 5.1.2 LAMEA Clinics Cancer Immunotherapy Market by Country
- 5.1.3 LAMEA Other End User Cancer Immunotherapy Market by Country

CHAPTER 6. LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY

- 6.1 Brazil Cancer Immunotherapy Market
 - 6.1.1 Brazil Cancer Immunotherapy Market by Technology
 - 6.1.2 Brazil Cancer Immunotherapy Market by Application
 - 6.1.3 Brazil Cancer Immunotherapy Market by End User
- 6.2 Argentina Cancer Immunotherapy Market
 - 6.2.1 Argentina Cancer Immunotherapy Market by Technology
 - 6.2.2 Argentina Cancer Immunotherapy Market by Application
 - 6.2.3 Argentina Cancer Immunotherapy Market by End User
- 6.3 UAE Cancer Immunotherapy Market
 - 6.3.1 UAE Cancer Immunotherapy Market by Technology
 - 6.3.2 UAE Cancer Immunotherapy Market by Application
 - 6.3.3 UAE Cancer Immunotherapy Market by End User
- 6.4 Saudi Arabia Cancer Immunotherapy Market
 - 6.4.1 Saudi Arabia Cancer Immunotherapy Market by Technology
 - 6.4.2 Saudi Arabia Cancer Immunotherapy Market by Application
 - 6.4.3 Saudi Arabia Cancer Immunotherapy Market by End User
- 6.5 South Africa Cancer Immunotherapy Market
 - 6.5.1 South Africa Cancer Immunotherapy Market by Technology
 - 6.5.2 South Africa Cancer Immunotherapy Market by Application
 - 6.5.3 South Africa Cancer Immunotherapy Market by End User
- 6.6 Nigeria Cancer Immunotherapy Market
 - 6.6.1 Nigeria Cancer Immunotherapy Market by Technology
 - 6.6.2 Nigeria Cancer Immunotherapy Market by Application
 - 6.6.3 Nigeria Cancer Immunotherapy Market by End User
- 6.7 Rest of LAMEA Cancer Immunotherapy Market
 - 6.7.1 Rest of LAMEA Cancer Immunotherapy Market by Technology
 - 6.7.2 Rest of LAMEA Cancer Immunotherapy Market by Application
 - 6.7.3 Rest of LAMEA Cancer Immunotherapy Market by End User

CHAPTER 7. COMPANY PROFILES

- 7.1 Amgen Inc.

- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental & Regional Analysis
- 7.1.4 Research and Development Expense
- 7.2 Merck & Company, Inc.
 - 7.2.1 Company Overview
 - 7.2.2 Financial Analysis
 - 7.2.3 Regional and Segmental Analysis
 - 7.2.4 Research & Development
- 7.3 Pfizer Inc.
 - 7.3.1 Company Overview
 - 7.3.2 Financial Analysis
 - 7.3.3 Segmental & Regional Analysis
 - 7.3.4 Revenue analysis by Region
 - 7.3.5 Research and Development
- 7.4 Immunomedics Inc.
 - 7.4.1 Company Overview
 - 7.4.2 Financial Analysis
 - 7.4.3 Revenue Analysis by Region
 - 7.4.4 Research and Development
- 7.5 Astrazeneca Plc.
 - 7.5.1 Company Overview
 - 7.5.2 Financial Analysis
 - 7.5.3 Segmental analysis
 - 7.5.4 Research & Development
- 7.6 F. Hoffmann-La Roche Ltd.
 - 7.6.1 Company Overview
 - 7.6.2 Financial Analysis
 - 7.6.3 Revenue & Segment analysis
 - 7.6.4 Research and Development
- 7.7 Eli Lilly and Company
 - 7.7.1 Company Overview
 - 7.7.2 Financial Analysis
 - 7.7.3 Segmental and Regional Analysis
 - 7.7.4 Research & Development Expense
- 7.8 Novartis AG
 - 7.8.1 Company Overview
 - 7.8.2 Financial Analysis
 - 7.8.3 Segmental and Regional Analysis

- 7.8.4 Research & Development Expense
- 7.9 Bristol-Myers Squibb Company
 - 7.9.1 Company Overview
- 7.1 Bayer AG
 - 7.10.1 Company Overview
 - 7.10.2 Financial Analysis
 - 7.10.3 Segmental and Regional Analysis
 - 7.10.4 Research & Development Expense

List Of Tables

LIST OF TABLES

TABLE 1 LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 2 LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 3 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 4 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 5 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 6 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 7 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 8 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 9 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 10 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 11 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 12 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 13 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 14 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 15 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 16 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 17 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 18 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 19 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY

COUNTRY, 2014 - 2017, USD MILLION

TABLE 20 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY
COUNTRY, 2018 - 2024, USD MILLION

TABLE 21 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY
COUNTRY, 2014 - 2017, USD MILLION

TABLE 22 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY
COUNTRY, 2018 - 2024, USD MILLION

TABLE 23 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET
BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 24 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET
BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 25 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2014 - 2017, USD MILLION

TABLE 26 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2018 - 2024, USD MILLION

TABLE 27 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 -
2017, USD MILLION

TABLE 28 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 -
2024, USD MILLION

TABLE 29 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2014 - 2017, USD MILLION

TABLE 30 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2018 - 2024, USD MILLION

TABLE 31 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY,
2014 - 2017, USD MILLION

TABLE 32 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY,
2018 - 2024, USD MILLION

TABLE 33 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2014 - 2017, USD MILLION

TABLE 34 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY
COUNTRY, 2018 - 2024, USD MILLION

TABLE 35 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 -
2017, USD MILLION

TABLE 36 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 -
2024, USD MILLION

TABLE 37 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 38 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 39 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 40 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 41 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 42 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 43 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 44 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 45 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 46 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 47 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 48 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 49 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 50 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 51 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 52 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 53 UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 54 UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 55 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 56 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 57 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 58 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 59 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017,

USD MILLION

TABLE 60 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024,
USD MILLION

TABLE 61 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 62 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 63 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 64 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 65 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2014 - 2017, USD MILLION

TABLE 66 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2018 - 2024, USD MILLION

TABLE 67 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER,
2014 - 2017, USD MILLION

TABLE 68 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER,
2018 - 2024, USD MILLION

TABLE 69 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 70 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 71 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 72 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 73 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2014 - 2017, USD MILLION

TABLE 74 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2018 - 2024, USD MILLION

TABLE 75 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER,
2014 - 2017, USD MILLION

TABLE 76 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER,
2018 - 2024, USD MILLION

TABLE 77 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 78 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 79 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 80 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 81 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 82 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 83 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 84 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 85 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 86 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 87 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 88 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 89 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 90 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 91 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 92 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 93 KEY INFORMATION-AMGEN INC.

TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.

TABLE 95 KEY INFORMATION- PFIZER INC.

TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.

TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.

TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.

TABLE 99 KEY INFORMATION – ELI LILLY AND COMPANY

TABLE 100 KEY INFORMATION – NOVARTIS AG

TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY

TABLE 102 KEY INFORMATION – BAYER AG

I would like to order

Product name: Latin America, Middle East & Africa Cancer Immunotherapy Market (2018 - 2024)

Product link: <https://marketpublishers.com/r/LA5F0A8F261EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LA5F0A8F261EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970